[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346091-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346091-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","projections-of-human-papillomavirus-hpv-vaccination-impact-on-non-cervical-cancer-outcomes-among-women-in-117-low-and-middle-income-countries-a-modelling-study","Projections of human papillomavirus (HPV) vaccination impact on non-cervical cancer outcomes among women in 117 low-and middle-income countries - a modelling study","","Human papillomavirus (HPV) drives both cervical and non-cervical cancers, including anal, oropharyngeal, vaginal, and vulvar malignancies. Because most assessments prioritize cervical disease, the broader effects of HPV vaccination in low- and middle-income countries (LMICs) remain less characterized. This modelling study projects health impacts of bivalent HPV vaccination across 117 LMICs from 2030 to 2100, incorporating mortality, HPV type distribution, demographics, and vaccine coverage, with sensitivity analyses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/projections-of-human-papillomavirus-hpv-vaccination-impact-on-non-cervical-cancer-outcomes-among-women-in-117-low-and-middle-income-countries-a-modelling-study/346091/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/projections-of-human-papillomavirus-hpv-vaccination-impact-on-non-cervical-cancer-outcomes-among-women-in-117-low-and-middle-income-countries-a-modelling-study/346091.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of this study on HPV vaccination?","Question",{"text":63,"@type":64},"To project the potential health impact of bivalent HPV vaccination on female non-cervical cancers beyond cervical cancer in 117 low- and middle-income countries from 2030 to 2100.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers estimate vaccination impact?",{"text":68,"@type":64},"They used a static cohort modelling approach that included country-specific cancer mortality, HPV type distribution, demographic projections, and vaccine coverage, followed by sensitivity analyses for key uncertainties.",{"name":70,"@type":61,"acceptedAnswer":71},"What reductions are projected for non-cervical cancers and deaths by 2100?",{"text":72,"@type":64},"The projections suggest prevention of roughly 3.02 million deaths from anal, oropharyngeal, vaginal, and vulvar cancers among women by 2100, alongside substantial reductions in cancer cases, with the African region showing the largest relative gains.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346091,1790162073,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Original research  \n Projections of human papillomavirus (HPV) vaccination impact on non-cervical cancer outcomes among women in 117 low-and middle-income countries: a modelling study  \nAarushi Tuli  ,1 Mark Jit,2 Kaja Abbas  ,3,4 Allison Portnoy  1,5  \nTo cite: Tuli A, Jit M, Abbas K, et al. Projections of human papillomavirus (HPV) vaccination impact on non-cervical cancer outcomes among women in 117 low-and middleincome countries: a modelling study. BMJ Glob Health 2026;11:e021127 . doi:10 . 1136/ bmjgh-2025-021127  \nHandling editor Yashi A Raj ► Additional supplemental material is published online only.  \nTo view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjgh-2025-021127](bmjgh-2025-021127)) .  \nReceived 25 June 2025 Accepted 11 August 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY. Published by BMJ Group. For numbered affiliations see end of article.  \nCorrespondence to  \nDr Allison Portnoy; [aportnoy@bu.edu](aportnoy@bu.edu)  \nABSTRACT  \nIntroduction Human papillomavirus (HPV) is a leading cause of both cervical and non-cervical cancers, including anal, oropharyngeal, vaginal and vulvar cancers. While most HPV vaccination impact assessments have focused on preventing cervical cancer among women, the broader benefits of vaccination against other HPV-attributable cancers in lowand middle-income countries (LMICs) remain less explored. Methods We used a static cohort model to assess the potential health impact of bivalent HPV vaccination on HPVattributable female non-cervical cancers in 117 LMICs from 2030 to 2100. The model incorporated country-specific data on cancer mortality, HPV type distribution, demographic projections and vaccine coverage. Sensitivity analyses were performed to account for uncertainties in cancer incidence, cancer mortality and HPV type distribution.  \nResults Our projections suggest that HPV vaccination could contribute to prevention of approximately five 90 000 cases of anal, 880 000 cases of oropharyngeal, 1.27 million cases of vaginal and 2.18 million cases of vulvar cancers over the analytic period. In total, 3.02 million deaths from these non-cervical cancers among women could be averted by 2100. The African region is expected to see the largest relative reductions in both cases and deaths while the European region showed the smallest gains. By the end of the century, 58 countries are projected to reach at least a 25% reduction in anal cancer mortality compared with just 25 countries for oropharyngeal cancer. These findings reflect substantial regional disparities in both burden and vaccination impact.  \nConclusion HPV vaccination holds considerable promise in reducing the burden of non-cervical cancers among women in LMICs, especially in regions with high incidence and limited access to care. Recognising and harnessing these broader benefits can strengthen the public health case for scaling up vaccine access, implementing regionspecific strategies and investing in equitable healthcare systems to decrease global disparities.  \nINTRODUCTION  \nHuman papillomavirus (HPV) is a leading cause of cancer-related mortality among  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Health-impact modelling has been used to project the impact of human papillomavirus (HPV) vaccination on prevention of cervical cancer.\u003Cbr>⇒ HPV is a leading cause of non-cervical cancers, including anal, oropharyngeal, vaginal and vulvar cancers.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This study estimated the impact of HPV vaccination on non-cervical female cancers, projecting the largest reductions in the African region.\u003Cbr>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY |\n\n⇒ In order to improve coverage of HPV vaccination programmes, it will be important to estimate additional cancer prevention benefits that can mitigate disease burden in low-and middle-income countries.  \nwomen worldwide.1 While almost all cervical canc","cbCaijB9uNXyKeyA","https://ap.wps.com/l/cbCaijB9uNXyKeyA","pdf",880134,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusion\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What is the purpose of this study on HPV vaccination?\",\"answer\":\"To project the potential health impact of bivalent HPV vaccination on female non-cervical cancers beyond cervical cancer in 117 low- and middle-income countries from 2030 to 2100.\"},{\"question\":\"How did the researchers estimate vaccination impact?\",\"answer\":\"They used a static cohort modelling approach that included country-specific cancer mortality, HPV type distribution, demographic projections, and vaccine coverage, followed by sensitivity analyses for key uncertainties.\"},{\"question\":\"What reductions are projected for non-cervical cancers and deaths by 2100?\",\"answer\":\"The projections suggest prevention of roughly 3.02 million deaths from anal, oropharyngeal, vaginal, and vulvar cancers among women by 2100, alongside substantial reductions in cancer cases, with the African region showing the largest relative gains.\"}]","Projections of human papillomavirus (HPV) vaccination impact on non-cervical cancer outcomes among women in 117 low-and middle-income countries - a modelling study | PDF",1790060052,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d3d27616e381be1383319ae23032604.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b2f9b390dcf7c293bae4707d5a7c78c.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6187079da38d788ede0ee7d13206917.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad56ab09b4c630f840109a6f176b857d.webp",980,1306]